Rezolute (NASDAQ:RZLT) versus ADMA Biologics (NASDAQ:ADMA) Head-To-Head Review

Rezolute (NASDAQ:RZLT) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings and analyst recommendations.

Profitability

This table compares Rezolute and ADMA Biologics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-64.81%	-59.37%
ADMA Biologics	28.80%	37.52%	27.87%

Risk and Volatility

Rezolute has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.

Institutional & Insider Ownership

83.0% of Rezolute shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 14.8% of Rezolute shares are held by insiders. Comparatively, 3.5% of ADMA Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Rezolute and ADMA Biologics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41 million	($0.93)	-3.26
ADMA Biologics	$510.17 million	7.22	$146.93 million	$0.60	25.78

ADMA Biologics has higher revenue and earnings than Rezolute. Rezolute is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for Rezolute and ADMA Biologics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	1	5	5	0	2.36
ADMA Biologics	0	1	0	2	3.33

Rezolute presently has a consensus target price of $7.63, indicating a potential upside of 151.65%. ADMA Biologics has a consensus target price of $32.00, indicating a potential upside of 106.85%. Given Rezolute’s higher possible upside, equities research analysts clearly believe Rezolute is more favorable than ADMA Biologics.

Summary

ADMA Biologics beats Rezolute on 9 of the 13 factors compared between the two stocks.

About Rezolute

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

About ADMA Biologics

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.